Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02447302 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis
A Phase 2 study, sponsored by Arena Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
NCT02447302 is a Phase 2 study that has completed, run by Arena Pharmaceuticals. The registered enrollment target is 156 participants.
The verdict
NCT02447302, a Phase 2 study, has completed, sponsored by Arena Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether etrasimod is a safe and effective treatment for ulcerative colitis.
Interventions
- DRUG Placebo
- DRUG Etrasimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2015-10-15 |
| Est. Completion | 2018-02-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02447302
The ClinicalTrials.gov registry entry for NCT02447302 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arena Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02447302 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02447302 about?
NCT02447302 is a clinical study titled "Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis". The purpose of this study is to determine whether etrasimod is a safe and effective treatment for ulcerative colitis.
What is the current status of trial NCT02447302?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2015-10-15. Estimated completion is 2018-02-14.
What interventions are being tested in trial NCT02447302?
The interventions under investigation include: Placebo (DRUG), Etrasimod (DRUG).
Who is sponsoring clinical trial NCT02447302?
This trial is sponsored by Arena Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.